Krystal Biotech Inc (KRYS) financials
Krystal Biotech revenue and earnings by year
Krystal Biotech's revenue was $389 million in the fiscal year to December 31, 2025, up 33.9% from the year before. Net income was $205 million, 52.6% of revenue.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 3 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 389 | 291 | 51 |
| Revenue growth | 33.9% | 473.0% | — |
| Gross profit | 366 | 270 | 48 |
| Gross margin | 94.1% | 93.1% | 93.9% |
| Operating income | 161 | 66 | -110 |
| Operating margin | 41.5% | 22.6% | -216.2% |
| Net income | 205 | 89 | 11 |
| Net margin | 52.6% | 30.7% | 21.6% |
| Diluted EPS | $6.84 | $3.00 | $0.39 |
| Free cash flow | 189 | 119 | -177 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open KRYS in Markets.
See also: KRYS valuation and P/E history · KRYS returns
No forecast, no recommendation. This page describes Krystal Biotech Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.